Key result
Early-onset SLE reaches ~33% 1-year remission, yet patients face worsening cardiovascular risk and quality of life.
Cohort (n=260)
Yes
Answers are grounded in this paper and cite their sources.
Objective To describe the clinical and serological features of a prospectively followed cohort of early diagnosed systemic lupus erythematosus (SLE) patients during a one-year follow-up period. Methods SLE patients with disease duration less than 12 months were consecutively enrolled in a multicentre, prospective study. At study entry and then every 6 months, a large panel of data was recorded. Results Of 260 patients enrolled, 185 had at least 12 months of follow-up; of these, 84.3% were female, 92.4% were Caucasians. Mean diagnostic delay was about 20 months; higher values of European Consensus Lupus Activity Measurement (ECLAM) and of organs/systems involved were both associated with shorter diagnostic delay. Clinical and serological parameters improved after study entry. However, patients' quality of life deteriorated and cardiovascular risk factors significantly increased. About one-third of patients with active disease at study entry went into remission (ECLAM = 0). Negative predictors for remission were: oral ulcers, arthritis, low C4, anti-SSB (Ro) antibodies and therapy with mycophenolate. There was a widespread use of glucocorticoids both at baseline and during follow-up. Conclusion Clinical symptoms and serological parameters improve during the first period after diagnosis. However, patients' quality of life deteriorates. The widespread use of glucocorticoids is probably the reason for the early significant increase of some cardiovascular risk factors.
No takes yet. Share an insight, caveat, or question.
Sebastiani et al. (2018) conducted a cohort in Systemic lupus erythematosus (SLE) (n=260). Early-onset systemic lupus erythematosus was evaluated on Remission (European Consensus Lupus Activity Measurement [ECLAM] = 0) and changes in clinical, serological, quality of life, and cardiovascular risk parameters. Early-onset SLE patients had about one-third remission (ECLAM=0) over 12 months, with improved clinical features but worse quality of life and cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: